# 2026年2月21日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 优化靶点失活以治疗携带NDM和PBP3突变的多重耐药菌：“更进一步”

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41718487)
**期刊：** Antimicrobial agents and chemotherapy
**PMID：** 41718487
**DOI：** 10.1128/aac.00887-25

### 第一部分 原文与翻译

**英文原标题：** Optimizing target inactivation to treat multidrug-resistant  with NDM and PBP3 mutations: "going the extra mile".

> **英文摘要：**
> A 65-year-old man without identifiable risk factors for multidrug-resistant pathogens was admitted with peritonitis, isolating NDM-producing from a rectal swab and intraoperative samples. After surgery, ceftazidime-avibactam/aztreonam was administered. Due to poor clinical response, he was switched to imipenem-relebactam/aztreonam, resulting in a successful outcome. Whole-genome sequencing detected and β-lactamases, PBP3 YRIN insertion, and mutated gene. This case illustrates the importance of considering different mechanisms of resistance when choosing combination therapy.

> **中文摘要：**
> 一名无明确多重耐药病原体风险因素的65岁男性因腹膜炎入院，其直肠拭子及术中样本分离出产NDM的[菌株]。术后，给予头孢他啶-阿维巴坦联合氨曲南治疗。由于临床疗效不佳，随后更换为亚胺培南-雷利巴坦联合氨曲南，最终取得了成功的治疗结果。全基因组测序检测到[多种]β-内酰胺酶、PBP3 YRIN插入以及突变的基因。本病例阐明了在选择联合治疗方案时，考虑不同耐药机制的重要性。

### 第二部分 AI 大师评价

该病例报告探讨了针对携带NDM酶及PBP3插入突变的复杂多重耐药菌感染的临床应对策略。研究核心在于记录了在头孢他啶-阿维巴坦联合方案失效后，通过转向亚胺培南-雷利巴坦联合氨曲南方案成功实现“靶点失活优化”的过程。全基因组测序进一步揭示了分子层面的多重抗性机制，强调了在面对复杂耐药表型时，精准选择新型联合用药方案的必要性。该研究为临床处理由于靶点突变导致常规联合疗法失败的耐药菌感染提供了宝贵的实证参考。

---

## 2. 调节异戊烯基转移酶中的芳香笼占据状态可实现稀有C-异戊烯基化黄酮的定向高效生产

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41714621)
**期刊：** Nature communications
**PMID：** 41714621
**DOI：** 10.1038/s41467-026-69706-4

### 第一部分 原文与翻译

**英文原标题：** Tuning aromatic cage occupancy in prenyltransferases enables selective and efficient production of rare c-prenylated flavonoids.

> **英文摘要：**
> C-prenylated flavonoids possess notable pharmaceutical potential, but their production is hindered by the challenging selective prenylation of their unstable polyphenolic cores. Natural prenyltransferases offer a direct route but suffer from low activity and incomplete mechanistic understanding. Here, we report a directed evolution strategy to reshape the active pocket of the prenyltransferase AtaPT, uncovering an aromatic cage that governs both regioselectivity and donor specificity. By tuning cage occupancy, we engineer three mutants with high chemo- and regioselectivity toward dimethylallyl diphosphate or geranyl pyrophosphate. Structural analysis and molecular simulations validate the role of the cage in guiding flavonoid prenylation. Notably, the aromatic cage mechanism observed in AtaPT is not unique and can be recapitulated in homologous enzymes. Introduction of the aromatic cage consistently enhances both activity and selectivity, confirming its crucial role. AtaPT mutants enable the efficient and scalable synthesis of 27 C-prenylated flavonoids, including 8 previously unreported compounds. With an integrated donor regeneration system, preparative-scale biotransformations achieve product titers up to 400 mg/L. This study establishes a selective and scalable biocatalytic platform for flavonoid prenylation and offers mechanistic insights for enzyme engineering.

> **中文摘要：**
> C-异戊烯基化黄酮具有显著的药用潜力，但其不稳定的多酚核心使得选择性异戊烯基化极具挑战性，从而阻碍了其生产。天然异戊烯基转移酶提供了一条直接途径，但存在活性低和机理解析不全的问题。在此，我们报道了一种重塑异戊烯基转移酶 AtaPT 活性口袋的定向进化策略，发现了一个决定区域选择性和供体特异性的芳香笼。通过调节芳香笼的占据状态，我们设计了三种对二甲基烯丙基二磷酸或香叶基焦磷酸具有高化学选择性和区域选择性的突变体。结构分析和分子模拟验证了该芳香笼在引导黄酮异戊烯基化中的作用。值得注意的是，在 AtaPT 中观察到的芳香笼机制并非特有，可以在同源酶中重现。芳香笼的引入一致地增强了活性和选择性，证实了其关键作用。AtaPT 突变体能够实现 27 种 C-异戊烯基化黄酮的高效、可规模化合成，其中包括 8 种先前未见报道的化合物。结合集成的供体再生系统，制备级生物转化实现的产品产量高达 400 mg/L。本研究建立了一个选择性且可规模化的黄酮异戊烯基化生物催化平台，并为酶工程提供了机理见解。

### 第二部分 AI 大师评价

该研究针对 C-异戊烯基化黄酮生物合成中活性与选择性的瓶颈，通过定向进化策略揭示了异戊烯基转移酶中关键的“芳香笼”调控机制。研究不仅通过对 AtaPT 的改造实现了对不同供体的高效识别与精确区域选择，还证明了该机制在同源酶中的普适性。最终构建的生物催化平台成功合成了多种稀有及新型黄酮衍生物，产量达到制备级水平，为天然产物的定制化生物制造提供了重要的理论依据和技术支撑。

---

## 3. 第1组肺动脉高压中高心输出量型心力衰竭的病理生理学及患病率

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41713952)
**期刊：** The European respiratory journal
**PMID：** 41713952
**DOI：** 10.1183/13993003.01871-2025

### 第一部分 原文与翻译

**英文原标题：** Pathophysiology and prevalence of high output heart failure in group 1 pulmonary hypertension.

> **英文摘要：**
> BACKGROUND: Pulmonary vasodilators increase cardiac output (CO) in group 1 PH and can cause high CO with unclear implications. OBJECTIVES: To describe pathophysiology of high CO in group 1 PH. METHODS: Clinical characteristics were compared among PVDOMICS group 1 PH participants by low (cardiac index (CI) <2.2 Lmin·m), normal, or high output (CO>8 L·min or CI>4 Lmin·m). MEASUREMENTS AND MAIN RESULTS: Of 449 group 1 PH participants, 23%(n=103) had low output, 68%(n=304) had normal CO and 9%(n=42) had high output. Increasing CO was associated with more intensive vasodilator use (triple therapy 11/19/33%,p=0.0008), with progressively lower PVR (p<0.0001). High output was associated with the lowest systemic vascular resistance (p<0.0001), with greater LV and LA enlargement (p<0.001 for all). High flow resulted in increase in LV and RV work at rest, and absolute/relative RV work during exercise (p<0.0001 for all). Despite greater exercise O delivery (p<0.0001), peripheral O utilization was impaired by O extraction ratio (p=0.001) and AVO difference (p=0.005), without incremental functional or survival benefit compared to normal output PH. After adjusting for baseline risk, high output had increased risk of death/transplant compared to normal output [adjusted HR 2.1 (95% 1.2-3.7), p=0.007]. In a validation cohort (n=37), 93% had normal CO at diagnosis, with the high output state developing in follow-up after vasodilator initiation. CONCLUSIONS: 1 in 10 patients with group 1 PH has a high output state which is most common in prevalent PH and related to vasodilator intensity, with adverse cardiac remodeling and myocardial workload. Further studies are needed to determine optimal vasodilator dosing with high output, and therapeutic interaction with vasodilator sparing therapies such as sotatercept.

> **中文摘要：**
> 背景：肺血管扩张剂可增加第1组肺动脉高压（PH）患者的心输出量（CO），并可能导致具有不明确临床意义的高CO状态。目的：描述第1组PH患者中高CO状态的病理生理学特征。方法：将PVDOMICS研究中第1组PH受试者的临床特征按照低心输出量（心脏指数 (CI) <2.2 L/min·m²）、正常心输出量或高心输出量（CO >8 L/min 或 CI >4 L/min·m²）进行对比。测量指标及主要结果：在449名第1组PH受试者中，23% (n=103) 为低心输出量，68% (n=304) 为正常CO，9% (n=42) 为高心输出量。CO的增加与更密集的血管扩张剂使用相关（三联疗法占比分别为11%/19%/33%，p=0.0008），且肺血管阻力（PVR）逐渐降低（p<0.0001）。高心输出量与最低的体血管阻力相关（p<0.0001），且伴有更显著的左心室（LV）和左心房（LA）扩大（均p<0.001）。高流量导致静息状态下LV和右心室（RV）做功增加，以及运动期间绝对/相对RV做功增加（均p<0.0001）。尽管运动期间氧输送量更高（p<0.0001），但由于氧摄取率（p=0.001）和动静脉氧差（p=0.005）受损，外周氧利用受到抑制，且与正常心输出量PH患者相比，未观察到额外的功能或生存获益。在调整基线风险后，与正常心输出量组相比，高心输出量组的死亡/移植风险增加 [调整后HR 2.1 (95% 1.2-3.7), p=0.007]。在验证队列 (n=37) 中，93%的患者在诊断时表现为正常CO，而高心输出量状态是在启动血管扩张剂治疗后的随访中出现的。结论：在第1组PH患者中，约有十分之一处于高心输出量状态，这在经治PH患者中最为常见，且与血管扩张剂治疗强度、不良心脏重塑及心肌负荷增加相关。需进一步研究以确定高心输出量状态下的最佳血管扩张剂剂量，以及其与sotatercept等非血管扩张性疗法的治疗相互作用。

### 第二部分 AI 大师评价

本研究揭示了第1组肺动脉高压（PH）中一种重要但常被忽视的临床现象——医源性或继发性高心输出量（CO）状态。通过对PVDOMICS队列的深度分析，作者发现约10%的患者在接受强效血管扩张治疗后会出现高CO，这种状态虽提高了氧输送，但因外周利用障碍及心脏重塑压力增加，不仅未改善预后，反而显著提升了死亡和移植风险。该研究具有极强的临床指导意义，警示医生在追求降低肺压的同时需警惕过度扩张血管带来的心脏过载，并为sotatercept等新型非血管扩张药物的临床应用提供了病理生理学依据。

---

## 4. 哮喘和慢阻肺（COPD）中黏液栓的病理生物学及治疗：现状与进展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41713949)
**期刊：** The European respiratory journal
**PMID：** 41713949
**DOI：** 10.1183/13993003.02358-2025

### 第一部分 原文与翻译

**英文原标题：** The pathobiology and treatment of mucus plugs in asthma and COPD: state of the art.

> **英文摘要：**
> Recent studies using computed tomography (CT) have uncovered a high prevalence of airway mucus plugs in patients with asthma and COPD. These mucus plugs persist in the same airways for years and often occur in patients without symptoms of cough and sputum production. Mucus plugs associate strongly with measures of airflow obstruction and disease morbidity in both asthma and COPD, and they occur and persist despite treatment with high doses of inhaled and oral corticosteroids. Thus, airway mucus plugs have emerged as an underappreciated airway pathology in asthma and COPD and a cause of persistent airflow obstruction and disease morbidity that can be specifically targeted for treatment. This narrative review covers the pathobiology of mucus plugs in asthma and COPD with three areas of emphasis: (i) Prevalence and clinical features; (ii) Mechanisms of formation and persistence; (iii) Current and emerging treatments.

> **中文摘要：**
> 近期利用计算机断层扫描（CT）的研究揭明了哮喘和慢阻肺（COPD）患者中气道黏液栓具有较高的盛行率。这些黏液栓在同一气道中可持续存在数年，且常发生于没有咳嗽和咳痰症状的患者。黏液栓与哮喘和慢阻肺中的气流受阻指标及疾病发病率强相关，且尽管接受了高剂量的吸入和口服皮质类固醇治疗，它们仍会出现并持续存在。因此，气道黏液栓已成为哮喘和慢阻肺中一种被低估的气道病理改变，也是导致持续性气流受阻和疾病发病率的原因，可作为特定的治疗目标。本叙述性综述涵盖了哮喘和慢阻肺中黏液栓的病理生物学，重点关注三个领域：（i）盛行率与临床特征；（ii）形成与持续存在的机制；（iii）当前及新兴的治疗方法。

### 第二部分 AI 大师评价

该综述系统总结了气道黏液栓在哮喘和COPD中的病理重要性，强调其作为导致持续性气流受阻的关键因素常被临床忽视。通过整合最新的CT影像学研究，文章揭示了黏液栓在激素治疗下的顽固性及与临床预后的密切联系。该文献不仅阐明了黏液栓形成的分子与物理机制，还前瞻性地讨论了新兴的精准治疗手段，为慢性气道疾病的靶向干预提供了重要的理论支撑。

---

## 5. 与遗传性出血性毛细血管扩张症相关的肺动脉高压：从遗传学到临床管理

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41713948)
**期刊：** The European respiratory journal
**PMID：** 41713948
**DOI：** 10.1183/13993003.02322-2025

### 第一部分 原文与翻译

**英文原标题：** Pulmonary hypertension associated with hereditary hemorrhagic telangiectasia: from genetics to clinical management.

> **英文摘要：**
> Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disorder with an estimated prevalence of 1/5000 to 1/7000. Pathogenic variants in three genes, , , and  all part of the transforming growth factor-beta (TGF-β) signaling pathway, account for over 90% of HHT cases. Clinically, HHT is characterised by recurrent epistaxis, gastrointestinal bleeding from mucocutaneous telangiectasias, and visceral arteriovenous malformations (AVMs), most commonly affecting the lungs, liver, and brain. Pulmonary hypertension (PH) is a recognised but heterogeneous complication of HHT, with reported prevalence ranging widely from 1.5% to 45%, depending on diagnostic methods and study populations. PH associated with HHT can result from distinct, and sometimes overlapping, pathophysiological mechanisms, including, among others, high cardiac output resulting from AVMs, isolated or associated with left heart disease and precapillary PH usually consistent with pulmonary arterial hypertension (PAH). Accurate hemodynamic classification by right heart catheterisation is essential to determine the predominant mechanism and guide appropriate therapeutic strategies. These may include embolisation or other management of AVMs, assessment for hepatic transplantation, administration of anti-angiogenic therapies such as anti-VEGF agents or the use of PAH-approved drugs in selected patients with precapillary involvement. Given the complexity of PH associated with HHT, optimal management requires a multidisciplinary approach within specialised centers experienced in both diseases. This review aims to provide a comprehensive overview of genetics, clinical phenotypes, diagnostic and therapeutic challenges in PH associated with HHT.

> **中文摘要：**
> 遗传性出血性毛细血管扩张症（HHT）是一种常染色体显性遗传病，估计患病率为 1/5000 至 1/7000。三个基因（、 和 ）的致病变异均属于转化生长因子-β（TGF-β）信号通路，占 HHT 病例的 90% 以上。临床上，HHT 的特征是反复发作的鼻出血、粘膜皮肤毛细血管扩张引起的胃肠道出血，以及最常累及肺、肝和脑的内脏动静脉畸形（AVMs）。肺动脉高压（PH）是 HHT 一种公认但具有异质性的并发症，报告的患病率差异很大，从 1.5% 到 45% 不等，具体取决于诊断方法和研究人群。与 HHT 相关的 PH 可能源于不同且有时重叠的病理生理机制，其中包括由 AVMs 导致的高心输出量、孤立或伴发左心疾病，以及通常与肺动脉高压（PAH）一致的毛细血管前 PH 等。通过右心导管检查进行准确的血流动力学分型，对于确定主要机制并指导适当的治疗策略至关重要。这些策略可能包括 AVMs 的栓塞或其他管理、肝移植评估、抗血管生成疗法（如抗 VEGF 药物）的应用，或在选定的毛细血管前受累患者中使用经批准的 PAH 药物。鉴于与 HHT 相关的 PH 的复杂性，优化管理需要由在这两种疾病方面均具有经验的专业中心采取多学科方法。本综述旨在全面概述 HHT 相关 PH 的遗传学、临床表型、诊断和治疗挑战。

### 第二部分 AI 大师评价

本综述深入探讨了遗传性出血性毛细血管扩张症（HHT）相关肺动脉高压（PH）的复杂性，核心价值在于清晰阐述了其异质性的病理生理机制。文章强调了右心导管检查在区分高排量型与毛细血管前型 PH 中的决定性作用，并为临床提供了从栓塞治疗到抗血管生成药物的多维度管理策略。尽管 HHT 相关 PH 的高患病率跨度提示了诊断标准的潜在差异，但该综述提出的多学科协作模式对提升此类罕见共病的诊疗水平具有重要临床指导意义。

---

## 6. 肺功能的循环蛋白质组学图谱

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41713944)
**期刊：** The European respiratory journal
**PMID：** 41713944
**DOI：** 10.1183/13993003.01528-2025

### 第一部分 原文与翻译

**英文原标题：** Circulating proteomic landscape of lung function.

> **英文摘要：**
> BACKGROUND: Large-scale genetic and epigenetic studies have identified numerous genes linked to lung function. However, proteomics, which can offer more direct insights into pathophysiologic processes, remains underexplored. We aimed to identify circulating proteins related to lung function. METHODS: In 20 823 adults (71% European, 15% African, and 15% Asian ancestries) across five cohorts we investigated spirometry parameters (FEV, FVC, and FEV/FVC) in relation to abundance in circulation of 4693 proteins assessed using the SOMAScan™ platform. Study-level associations were determined using robust linear regression, adjusting for confounders including age, sex, height, weight, and smoking. Results were then meta-analysed using inverse-variance weighting. RESULTS: In this multi-ancestry population, 1055 proteins were significantly associated with a lung function trait after Bonferroni correction (p<1×10). The 473 enriched pathways identified include those involving inflammation and organismal injury. Protein-protein networks indicate potential orchestrators of lung function, including STAT3 and EGFR. Associations with 411 proteins were validated in the UK Biobank using the Olink 3K platform (560 overlapping proteins). 179 proteins identified were related to COPD in our data. While most associated proteins are likely biomarkers of impaired lung function, Mendelian randomisation provides preliminary evidence suggesting potential causality for 34 proteins. Our findings include known biomarkers of lung diseases including COPD. Notably, 89% of associated proteins have not been previously implicated in lung function. CONCLUSION: This comprehensive investigation identified novel protein-lung function associations that could improve understanding of lung disease pathogenesis, aid in the discovery of circulating biomarkers and accelerate development of new management strategies for respiratory conditions.

> **中文摘要：**
> 背景：大规模遗传学和表观遗传学研究已经确定了许多与肺功能相关的基因。然而，蛋白质组学可以为病理生理过程提供更直接的见解，但目前仍未得到充分探索。本研究旨在鉴定与肺功能相关的循环蛋白质。方法：我们在五个队列的20,823名成年人（包含71%欧洲裔、15%非洲裔和15%亚洲裔）中，研究了肺通气功能参数（FEV1、FVC和FEV1/FVC）与使用SOMAScan™平台评估的4693种循环蛋白质丰度之间的关系。研究层面的关联性采用稳健线性回归确定，并校正了包括年龄、性别、身高、体重和吸烟在内的混杂因素。随后使用逆方差加权法对结果进行了荟萃分析。结果：在这一多族裔人群中，经过Bonferroni校正后，共有1055种蛋白质与肺功能特征显著相关（p<1×10⁻⁵）。确定的473条富集通路包括涉及炎症和机体损伤的通路。蛋白质-蛋白质相互作用网络指出了肺功能的潜在协调因子，包括STAT3和EGFR。在英国生物样本库（UK Biobank）中，利用Olink 3K平台验证了与411种蛋白质的关联（560种重叠蛋白质）。在我们的数据中，确定的179种蛋白质与慢性阻塞性肺疾病（COPD）相关。虽然大多数相关蛋白质可能是肺功能受损的生物标志物，但孟德尔随机化分析为34种蛋白质的潜在因果关系提供了初步证据。我们的发现涵盖了包括COPD在内的已知肺部疾病生物标志物。值得注意的是，89%的相关蛋白质此前从未被发现与肺功能有关。结论：这一全面的调查确定了新的蛋白质与肺功能的关联，有助于加深对肺部疾病发病机制的理解，辅助循环生物标志物的发现，并加速呼吸系统疾病新管理策略的开发。

### 第二部分 AI 大师评价

本研究通过对两万余名多族裔受试者进行大规模蛋白质组学分析，系统性地构建了肺功能的循环蛋白质图谱，鉴定出1055种相关蛋白质，其中89%为首次发现。研究不仅利用UK Biobank进行了跨平台验证，还结合孟德尔随机化探讨了潜在的因果关系，并锁定了STAT3和EGFR等关键调控节点。该成果极大地丰富了肺部疾病的生物标志物库，为理解肺功能减退的分子机制及开发新的干预靶点提供了高质量的证据支持。

---

## 7. 氨基糖苷类药物在中空纤维感染模型中增强美罗培南/韦博巴坦对产KPC酶肺炎克雷伯菌的活性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41711574)
**期刊：** Antimicrobial agents and chemotherapy
**PMID：** 41711574
**DOI：** 10.1128/aac.01365-25

### 第一部分 原文与翻译

**英文原标题：** Aminoglycosides enhance meropenem/vaborbactam activity against KPC-producing  in the hollow fiber infection model.

> **英文摘要：**
> Meropenem/vaborbactam is a preferred treatment option for KPC-producing  (KPC-Kp) infections, but clinical cure rates remain suboptimal when it is used alone. This study aimed to assess the pharmacodynamic activity of meropenem/vaborbactam alone and in combination with an aminoglycoside in the hollow fiber infection model (HFIM). The HFIM was used to simulate meropenem/vaborbactam and aminoglycoside pharmacokinetic profiles that approximated antibiotic exposures in the plasma and lung epithelial lining fluid (ELF) following human doses against four meropenem/vaborbactam-susceptible KPC-Kp isolates. Two isolates had lower meropenem/vaborbactam MICs (0.125/8 to 0.25/8 mg/L; NU-CRE105 and NU-CRE244), and two had higher MICs (2/8 mg/L; AR-1049 and AR-1054). Against NU-CRE105 and NU-CRE244, meropenem/vaborbactam was bactericidal and caused >5.7 log CFU/mL reductions by 48 h. Antibiotic exposures mimicking those in plasma and ELF yielded similar bacterial killing. Despite the robust activity of meropenem/vaborbactam alone, combinations with an aminoglycoside were synergistic, providing ≥2 log CFU/mL better killing of NU-CRE105 and NU-CRE244 than either monotherapy for ~40% of the experiment. Against AR-1049 and AR-1054, meropenem/vaborbactam monotherapy mimicking ELF exposures generated 2.9-5.2 log CFU/mL reductions at 48 h. However, meropenem/vaborbactam resistance emerged by 168 h. Combinations with an aminoglycoside displayed 4.7-7.5 log CFU/mL greater killing than either monotherapy at 168 h and repressed meropenem/vaborbactam resistance. Meropenem/vaborbactam remains an important agent against KPC-Kp. However, pneumonia caused by KPC-Kp isolates with MICs near the susceptibility breakpoint (≤4/8 mg/L) may reduce the pharmacodynamic activity of meropenem/vaborbactam and permit resistance to emerge. Aminoglycosides represent a promising adjunct to meropenem/vaborbactam for select KPC-Kp isolates, owing to their capacity to enhance bacterial killing and suppress resistance.

> **中文摘要：**
> 美罗培南/韦博巴坦是治疗产KPC酶肺炎克雷伯菌（KPC-Kp）感染的首选方案，但单独使用时的临床治愈率仍不理想。本研究旨在利用中空纤维感染模型（HFIM）评估美罗培南/韦博巴坦单独及与氨基糖苷类药物联用时的药效学活性。HFIM被用于模拟美罗培南/韦博巴坦和氨基糖苷类药物在人体给药后的血浆和肺上皮衬液（ELF）中的药代动力学特征，以针对四株对美罗培南/韦博巴坦敏感的KPC-Kp分离株进行研究。其中两株分离株具有较低的美罗培南/韦博巴坦最小抑菌浓度（MIC为0.125/8至0.25/8 mg/L；NU-CRE105和NU-CRE244），另外两株具有较高的MIC（2/8 mg/L；AR-1049和AR-1054）。针对NU-CRE105和NU-CRE244，美罗培南/韦博巴坦具有杀菌作用，并在48小时内使细菌载量减少了>5.7 log CFU/mL。模拟血浆和ELF中的抗生素暴露产生了相似的杀菌效果。尽管美罗培南/韦博巴坦单药具有强大的活性，但与氨基糖苷类联用具有协同作用，在大约40%的实验时间内，对NU-CRE105和NU-CRE244的杀菌效果比任何一种单药治疗高出≥2 log CFU/mL。针对AR-1049和AR-1054，模拟ELF暴露的美罗培南/韦博巴坦单药治疗在48小时时使细菌减少了2.9-5.2 log CFU/mL。然而，到168小时时出现了美罗培南/韦博巴坦耐药性。与氨基糖苷类联用在168小时时的杀菌效果比任何一种单药治疗高出4.7-7.5 log CFU/mL，并抑制了美罗培南/韦博巴坦耐药性的产生。美罗培南/韦博巴坦仍是抗KPC-Kp的重要药物。然而，由MIC接近敏感性折点（≤4/8 mg/L）的KPC-Kp菌株引起的肺炎可能会降低美罗培南/韦博巴坦的药效学活性，并允许耐药性产生。由于氨基糖苷类药物具有增强杀菌能力和抑制耐药性的潜力，对于特定的KPC-Kp分离株，它们是美罗培南/韦博巴坦极具前景的辅助治疗药物。

### 第二部分 AI 大师评价

本研究通过中空纤维感染模型（HFIM）系统评估了美罗培南/韦博巴坦与氨基糖苷类联合用药的药效学价值。研究精准模拟了人体不同组织部位（血浆与肺部）的药物暴露，揭示了对于MIC接近折点的KPC-Kp菌株，单药治疗存在明显的耐药风险。其实践意义在于证明了氨基糖苷类作为辅助药物，能够通过增强协同杀菌和抑制耐药演化，显著优化重症KPC-Kp感染的治疗预后，为临床制定联合给药方案提供了坚实的实验依据。

---

## 8. 2020-2023年某三级医院ST11-KL25型与ST11-KL64型高毒力碳青霉烯耐药肺炎克雷伯菌的基因组、表型及临床特征比较研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41711572)
**期刊：** Antimicrobial agents and chemotherapy
**PMID：** 41711572
**DOI：** 10.1128/aac.01080-25

### 第一部分 原文与翻译

**英文原标题：** Comparative genomic, phenotypic, and clinical characterization of ST11-KL25 and ST11-KL64 hypervirulent carbapenem-resistant  in a tertiary hospital, 2020-2023.

> **英文摘要：**
> Hypervirulent carbapenem-resistant  (hv-CRKP) poses a significant challenge in healthcare settings due to its combination of high virulence and multidrug resistance. In China, ST11 is the predominant lineage, with KL64 and the recently identified KL25 as key capsular subtypes. The clinical and genomic characteristics of ST11-KL25 remain insufficiently characterized. A total of 239 hv-CRKP isolates collected from 2020 to 2023 were analyzed. Molecular typing, antimicrobial susceptibility testing, whole-genome sequencing, and phenotypic assays were used to compare the epidemiology, resistance mechanisms, and virulence traits of ST11-KL25 and ST11-KL64. Clinical data were reviewed to assess infection characteristics. ST11 accounted for 87.9% (210/239) of hv-CRKP isolates. Among ST11 isolates, KL64 (54.7%, 104/190) and KL25 (45.3%, 86/190) were the predominant capsular types. Phylogenetic analysis suggested that ST11-KL25 may have originated from KL64 through capsular switching, with increasing prevalence after 2021. Both sublineages exhibited extensive drug resistance; however, ST11-KL64 showed broader resistance, including higher rates of ceftazidime-avibactam and polymyxin resistance. Phenotypically, ST11-KL25 demonstrated greater competitive fitness and biofilm formation, while ST11-KL64 displayed higher  virulence in the  model. ST11-KL25 and ST11-KL64 exhibit distinct adaptation strategies within hv-CRKP. KL25 seems to be a stable, colonization-adapted subtype with consistent resistance and moderate virulence, while KL64 is more invasive, with broader resistance and higher virulence. Subtype-specific surveillance and intervention are essential to limit their spread and protect patient and public health.

> **中文摘要：**
> 高毒力碳青霉烯耐药肺炎克雷伯菌（hv-CRKP）由于其融合了高毒力和多重耐药性，对医疗机构构成了重大挑战。在中国，ST11是主要流行谱系，其中KL64和近期发现的KL25是关键的荚膜亚型。目前，ST11-KL25的临床和基因组特征尚未得到充分描述。本研究分析了2020年至2023年间收集的共239株hv-CRKP分离株。通过分子分型、药敏试验、全基因组测序和表型实验，比较了ST11-KL25和ST11-KL64的流行病学、耐药机制及毒力特征，并审阅了临床数据以评估感染特征。结果显示，ST11占hv-CRKP分离株的87.9%（210/239）。在ST11分离株中，KL64（54.7%, 104/190）和KL25（45.3%, 86/190）是主要的荚膜类型。系统发育分析表明，ST11-KL25可能通过荚膜转换起源于KL64，且在2021年后流行率不断上升。两个亚系均表现出广泛的耐药性；然而，ST11-KL64显示出更广泛的耐药谱，包括更高的头孢他啶/阿维巴坦和多黏菌素耐药率。在表型上，ST11-KL25表现出更强的竞争适应性和生物膜形成能力，而ST11-KL64在大蜡螟模型中显示出更高的毒力。ST11-KL25和ST11-KL64在hv-CRKP中表现出截然不同的适应策略：KL25似乎是一个稳定的、适应定植的亚型，具有一致的耐药性和中等毒力；而KL64更具侵袭性，具有更广泛的耐药性和更高的毒力。针对特定亚型的监测和干预对于限制其传播、保护患者及公众健康至关重要。

### 第二部分 AI 大师评价

本研究深入对比了中国高毒力碳青霉烯耐药肺炎克雷伯菌（hv-CRKP）中最主要的ST11谱系下两个关键亚型KL25与KL64。研究通过全基因组测序和表型实验，首次揭示了KL25可能源于KL64的荚膜转换，并详细阐述了两者在进化上的分化策略：KL25侧重于环境定植与竞争适应，而KL64则演化出更高的侵袭力和广谱耐药性。这一发现对于临床识别高风险菌株及制定亚型特异性的防控措施具有重要的学术价值和实践意义。

---

## 9. 接受静脉-静脉体外膜肺氧合治疗的急性呼吸窘迫综合征患者全身抗凝与临床结局的相关性：一项多中心倾向性加权研究的启示

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41711512)
**期刊：** Critical care medicine
**PMID：** 41711512
**DOI：** 10.1097/CCM.0000000000007071

### 第一部分 原文与翻译

**英文原标题：** Association Between Systemic Anticoagulation and Outcomes in Patients With Acute Respiratory Distress Syndrome Receiving Venovenous Extracorporeal Membrane Oxygenation: Insights From a Multicenter Propensity-Weighted Study.

> **英文摘要：**
> OBJECTIVE: To evaluate whether systemic anticoagulation therapy affects the survival of adult patients receiving venovenous extracorporeal membrane oxygenation (VV-ECMO) for acute respiratory distress syndrome (ARDS). DESIGN: Multicenter retrospective study. SETTING: Twenty-four ICUs in Japan. PATIENTS: Six hundred and ninety-five patients received VV-ECMO for ARDS. Patients were divided into the anticoagulation group and the no-anticoagulation group according to whether or not they received anticoagulant therapy. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: In the propensity score-overlap-weighted analysis, there was no significant difference in the 28-day survival (85.8% vs. 81.5%, p = 0.50) between the two groups. The 60-day survival, ECMO duration, circuit exchanges, bleeding complications, and transfusion volumes were also comparable. The anticoagulation group had a significantly higher average activated partial thromboplastin time during ECMO (51.3 s vs. 39.3 s, p < 0.01). These findings remained consistent in the sensitivity analysis using inverse probability of treatment weighting. CONCLUSIONS: Systemic anticoagulation was not associated with short-term survival. Anticoagulation-free VV-ECMO may be feasible in patients at high-bleeding risk, but safety remains uncertain. Further studies should clarify optimal anticoagulation strategies.

> **中文摘要：**
> 目的：评估全身抗凝治疗是否影响因急性呼吸窘迫综合征（ARDS）接受静脉-静脉体外膜肺氧合（VV-ECMO）治疗的成年患者的生存率。设计：多中心回顾性研究。地点：日本的24个重症监护病房（ICU）。患者：695名因ARDS接受VV-ECMO治疗的患者。根据是否接受抗凝治疗，将患者分为抗凝组和非抗凝组。干预措施：无。测量指标与主要结果：在倾向评分重叠加权分析中，两组之间的28天生存率（85.8% vs. 81.5%，p = 0.50）无显著差异。60天生存率、ECMO持续时间、管路更换、出血并发症和输血量也具有可比性。抗凝组在ECMO期间的平均活化部分凝血活酶时间显著更高（51.3秒 vs. 39.3秒，p < 0.01）。在应用治疗加权逆概率进行的敏感性分析中，这些发现保持一致。结论：全身抗凝与短期生存率无关。对于高出血风险患者，无抗凝VV-ECMO可能是可行的，但其安全性仍不确定。未来的研究应进一步明确最佳抗凝策略。

### 第二部分 AI 大师评价

本研究利用日本多中心回顾性数据，通过倾向评分重叠加权法探讨了VV-ECMO治疗ARDS时全身抗凝对预后的影响。研究结果显示，抗凝治疗与非抗凝治疗在28天生存率、并发症及管路寿命等方面均无显著差异。这一发现对传统“ECMO必须抗凝”的临床观念提出了挑战，提示对于高出血风险患者实施无抗凝策略具有潜在可行性。尽管研究具有较强的临床参考价值，但受限于其回顾性设计的局限性，最佳抗凝策略仍需高质量的前瞻性研究进一步明确。

---

## 10. 结节病：最前沿综述

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41232941)
**期刊：** The European respiratory journal
**PMID：** 41232941
**DOI：** 10.1183/13993003.01324-2025

### 第一部分 原文与翻译

**英文原标题：** Sarcoidosis: a state-of-the-art review.

> **英文摘要：**
> Sarcoidosis is a complex systemic granulomatous disease that can affect multiple organs, with pulmonary involvement being the most common. Its pathogenesis involves genetic predisposition and chronic immune dysregulation, which increase susceptibility to environmental or endogenous triggers, leading to an aberrant immune response. Imaging plays a central role in diagnosis and has evolved from traditional chest radiography Scadding staging to a computed tomography-based classification and radiomics that improves disease phenotyping. Due to its variable presentation, diagnosing sarcoidosis and attributing symptoms to the disease can be challenging; therefore, awareness and consideration of alternative diagnoses remain essential. The clinical course of sarcoidosis is unpredictable; many patients do not require therapy. Treatment decisions must be individualised, balancing disease severity, risk of organ damage, quality of life and potential toxicity of medication. However, the lack of both reliable prognostic tools and clear criteria for high-risk cases contributes to substantial heterogeneity in disease management. While the guidelines still recommend corticosteroids as first-line treatment, recent data show that methotrexate and prednisone have comparable effects on pulmonary function, although differ in side-effect profiles and time to efficacy. For refractory cases, second-line therapy involves combining or switching drugs, with anti-tumour necrosis factor agents representing third-line options, ideally in expert hands. Novel therapies targeting pathways involved in disease pathogenesis are under investigation. There is growing consensus on the need to revise current treatment algorithms to minimise corticosteroid use and adopt more evidence-based approaches. Future priorities include identifying prognostic biomarkers, refining trial design and establishing meaningful end-points to improve individualised care for the heterogeneous population of patients with sarcoidosis.

> **中文摘要：**
> 结节病是一种复杂的全身性肉芽肿性疾病，可累及多个器官，其中肺部受累最为常见。其发病机制涉及遗传易感性和慢性免疫失调，这增加了对环境或内源性触发因素的敏感性，从而导致异常的免疫反应。影像学在诊断中起着核心作用，并已从传统的胸部X线Scadding分期演变为基于计算机断层扫描的分类和放射组学，从而改善了疾病的表型分析。由于其临床表现多样，诊断结节病并将症状归因于该病可能具有挑战性；因此，保持对鉴别诊断的认识和考虑仍然至关重要。结节病的临床过程不可预测；许多患者不需要治疗。治疗决策必须个体化，权衡疾病严重程度、器官损伤风险、生活质量和药物的潜在毒性。然而，由于缺乏可靠的预后工具和高风险病例的明确标准，导致疾病管理存在显著的异质性。虽然指南仍推荐皮质类固醇作为一线治疗，但最近的数据显示，甲氨蝶呤和泼尼松对肺功能的影响相当，尽管在副作用特征和起效时间方面有所不同。对于难治性病例，二线治疗涉及联合或更换药物，抗肿瘤坏死因子制剂代表三线选择，理想情况下应由专家操作。针对疾病发病机制相关通路的新型疗法正在研究中。人们对于修订现有治疗方案以尽量减少皮质类固醇使用并采用更多基于证据的方法的必要性日益达成共识。未来的重点包括确定预后生物标志物、改进临床试验设计以及建立有意义的终点，以改善结节病异质性患者群体的个体化护理。

### 第二部分 AI 大师评价

本综述全面梳理了结节病从发病机制到前沿疗法的最新进展，系统地阐述了影像学评价由Scadding分期向放射组学演进的趋势。文章深刻剖析了当前临床管理的痛点，特别是预后评估工具缺失导致的治疗异质性，并重点对比了甲氨蝶呤与糖皮质激素的疗效差异。其核心价值在于提出了减少激素依赖、向精准个体化治疗转型的共识建议，为未来临床试验的设计和生物标志物的开发指明了方向。

---

## 11. 白细胞ADAM10和ADAM17调节细菌性及病毒性肺炎的疾病严重程度和全身预后

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41198388)
**期刊：** The European respiratory journal
**PMID：** 41198388
**DOI：** 10.1183/13993003.02060-2024

### 第一部分 原文与翻译

**英文原标题：** Leukocytic ADAM10 and ADAM17 modulate disease severity and systemic outcome in bacterial and viral pneumonia.

> **英文摘要：**
> BACKGROUND: Pneumonia caused by viral or bacterial pathogens such as severe acute respiratory syndrome coronavirus 2 or  may result in life-threatening disease with a strong contribution of protease dysregulation. The present study aimed to systematically characterise the contribution of ADAM10 and ADAM17 on leukocytes and circulating exosomes to viral and bacterial pneumonia. METHODS: The analysis of coronavirus disease 2019 (COVID-19) and bacterial pneumonia patient samples was combined with  experiments in conditional knockout animals lacking either ADAM10 or ADAM17 in leukocytes and cell culture experiments for mechanistic studies. RESULTS: Hospitalised bacterial pneumonia and COVID-19 patients displayed a severity dependent increase of ADAM10 and ADAM17 activity on exosomes. These exosomes caused pathophysiological changes of cardiomyocytes and the endothelial barrier. In a pre-clinical murine pneumonia model, we observed that leukocytes contributed to this increase in exosomal proteolytic activity. In the local environment of the lung, ADAM10 orchestrated a pro-inflammatory response with M1 macrophage polarisation, increased reactive oxygen species (ROS) generation, cytokine release, tissue damage and oedema formation, whereas ADAM17 seemed to dampen the initial inflammatory response to an anti-infective, ROS-balanced level. CONCLUSION: Leukocytic ADAM10 and ADAM17 and their release on exosomes may constitute relevant regulatory elements in bacterial and viral pneumonia, with a potential contribution of exosomes to disease progression and systemic inflammatory responses. Therefore, the diagnostic, prognostic and therapeutic value of ADAM10 and ADAM17 should be evaluated in further preclinical and translational studies, addressing the changes of the immune response and exosomes as cargo vehicles both at local site and for the prevention of systemic effects.

> **中文摘要：**
> 背景：由病毒或细菌病原体（如严重急性呼吸综合征冠状病毒2型）引起的肺炎可能导致危及生命的疾病，其中蛋白酶失调起到了重要作用。本研究旨在系统地表征白细胞和循环外泌体上的ADAM10和ADAM17对病毒性和细菌性肺炎的影响。方法：将2019冠状病毒病（COVID-19）和细菌性肺炎患者样本的分析与在白细胞中缺乏ADAM10或ADAM17的条件性敲除动物实验以及用于机制研究的细胞培养实验相结合。结果：住院治疗的细菌性肺炎和COVID-19患者表现出外泌体上ADAM10和ADAM17活性随严重程度增加的现象。这些外泌体引起了心肌细胞和内皮屏障的病理生理变化。在临床前小鼠肺炎模型中，我们观察到白细胞促成了这种外泌体蛋白水解活性的增加。在肺部局部环境中，ADAM10通过M1巨噬细胞极化、增加活性氧（ROS）生成、细胞因子释放、组织损伤和水肿形成来协调促炎反应，而ADAM17似乎能将最初的炎症反应抑制到抗感染、ROS平衡的水平。结论：白细胞ADAM10和ADAM17及其在外泌体上的释放可能构成细菌性和病毒性肺炎中相关的调节元件，且外泌体可能对疾病进展和全身炎症反应产生影响。因此，应在进一步的临床前和转化研究中评估ADAM10和ADAM17的诊断、预后和治疗价值，重点关注免疫反应的变化以及外泌体作为局部和预防全身效应的载体作用。

### 第二部分 AI 大师评价

本研究通过结合临床样本、条件性敲除小鼠模型及细胞实验，深入探讨了ADAM10和ADAM17在重症肺炎中的作用。研究创新性地揭示了这两种蛋白酶通过外泌体介导，不仅影响肺部局部炎症环境（如巨噬细胞极化和ROS产生），还参与了导致心肌和内皮损伤的全身性效应。发现ADAM10与ADAM17在调节炎症反应中呈现出差异化的甚至对立的角色，这为临床区分肺炎严重程度提供了潜在的外泌体生物标志物，并为精准靶向蛋白酶治疗肺炎及其全身并发症提供了重要的理论依据。

---

速递结束，祝您工作愉快！